On the first day of the JPM Medical Conference, pharmaceutical giants are announcing new strategies. Could the mergers and acquisitions in Biomedical begin in 2025?

In 2025, the Biomedical mergers and acquisitions will begin.

wallstreetcn35minutes ago

Express News | AbbVie collaborates with Xiansheng Zaiming to develop a candidate drug for multiple myeloma.

Breakings8minutes ago

AbbVie To Go Ex-Dividend On January 15th, 2025 With 1.64 USD Dividend Per Share

January 13th (Eastern Time) - $AbbVie(ABBV.US)$ is trading ex-dividend on January 15th, 2025.Shareholders of record on January 15th, 2025 will receive 1.64 USD dividend per share on February 14th, 202

Futu News09:00

SIMCERE PHARMA's subsidiary has signed an overseas license option agreement with AbbVie for SIM0500.

SIMCERE PHARMA (02096) announced that on January 13, 2025, its subsidiary ShanDong SIMCERE Biopharmaceutical Co., Ltd. (ShanDong SIMCERE) entered into a licensing option agreement with a subsidiary of AbbVie Inc. (stock code: ABBV). Under the terms of the agreement, AbbVie will hold the licensing option rights for the investigational new candidate drug SIM0500. SIM0500 is currently undergoing Phase I clinical trials for patients with relapsed or refractory multiple myeloma (MM) in China and the United States. According to the terms of the agreement, the group will receive an upfront payment from AbbVie, as well as the most...

Sina Hong Kong Stock.08:22

AbbVie (NYSE:ABBV) Is Paying Out A Larger Dividend Than Last Year

Yahoo Finance02:35

ConcertAI Presents at 43rd Annual J.P. Morgan Healthcare Conference: 2024 Results and 2025-2028 AI Solutions Roadmap

Businesswire01:00